BPG is committed to discovery and dissemination of knowledge
Cited by in F6Publishing
For: Elsallabi O, Bhatt VR, Dhakal P, Foster KW, Tendulkar KK. Hematopoietic Stem Cell Transplant-Associated Thrombotic Microangiopathy. Clin Appl Thromb Hemost 2016;22:12-20. [PMID: 26239316 DOI: 10.1177/1076029615598221] [Cited by in Crossref: 39] [Cited by in F6Publishing: 40] [Article Influence: 5.6] [Reference Citation Analysis]
Number Citing Articles
1 Zhang Z, Wang H, Qi J, Tang Y, Cai C, Zhou M, Pan T, Wu D, Han Y. Acute graft-versus-host disease increase risk and accuracy in prediction model of transplantation-associated thrombotic microangiopathy in patients with myelodysplastic syndrome. Ann Hematol 2022. [PMID: 35357522 DOI: 10.1007/s00277-022-04820-z] [Cited by in Crossref: 1] [Article Influence: 1.0] [Reference Citation Analysis]
2 Leimi L, Jahnukainen K, Olkinuora H, Meri S, Vettenranta K. Early vascular toxicity after pediatric allogeneic hematopoietic stem cell transplantation. Bone Marrow Transplant 2022. [PMID: 35177827 DOI: 10.1038/s41409-022-01607-8] [Reference Citation Analysis]
3 Gomez-Ganda L, Benitez-Carabante MI, Fernandez-Polo A, Muñoz-Lopez M, Renedo-Miro B, Ariceta G, Diaz De Heredia C. Use of Eculizumab in Pediatric Patients With Transplant Associated Thrombotic Microangiopathy. Front Pediatr 2021;9:761726. [PMID: 34858907 DOI: 10.3389/fped.2021.761726] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 2.0] [Reference Citation Analysis]
4 Páramo JA. Microvascular thrombosis and clinical implications. Medicina Clínica (English Edition) 2021;156:609-614. [DOI: 10.1016/j.medcle.2020.12.025] [Reference Citation Analysis]
5 Hematopoietic Stem Cell Application Group, Chinese Society of Hematology, Chinese Medical Association. [Chinese consensus on the diagnosis and management of transplant-associated thrombotic microangiopathy (2021)]. Zhonghua Xue Ye Xue Za Zhi 2021;42:177-84. [PMID: 33910301 DOI: 10.3760/cma.j.issn.0253-2727.2021.03.001] [Cited by in F6Publishing: 1] [Reference Citation Analysis]
6 Cugno M, Berra S, Depetri F, Tedeschi S, Griffini S, Grovetti E, Caccia S, Cresseri D, Messa P, Testa S, Giglio F, Peyvandi F, Ardissino G. IgM Autoantibodies to Complement Factor H in Atypical Hemolytic Uremic Syndrome. J Am Soc Nephrol 2021;32:1227-35. [PMID: 33712527 DOI: 10.1681/ASN.2020081224] [Cited by in Crossref: 5] [Cited by in F6Publishing: 5] [Article Influence: 5.0] [Reference Citation Analysis]
7 Páramo JA. [Microvascular thrombosis and clinical implications]. Med Clin (Barc) 2021;156:609-14. [PMID: 33875227 DOI: 10.1016/j.medcli.2020.12.042] [Cited by in Crossref: 2] [Cited by in F6Publishing: 1] [Article Influence: 2.0] [Reference Citation Analysis]
8 Valério P, Barreto JP, Ferreira H, Chuva T, Paiva A, Costa JM. Thrombotic microangiopathy in oncology - a review. Transl Oncol 2021;14:101081. [PMID: 33862523 DOI: 10.1016/j.tranon.2021.101081] [Cited by in Crossref: 5] [Cited by in F6Publishing: 4] [Article Influence: 5.0] [Reference Citation Analysis]
9 Mueller NJ. Changing Definition of Immunosuppression: Targeted Therapies and Resulting Emerging Infections and Their Prevention. Emerging Transplant Infections 2021. [DOI: 10.1007/978-3-030-25869-6_13] [Reference Citation Analysis]
10 Miller R, Schlueter A. Transplant Infectious Disease Evaluation of Cytopenias. Emerging Transplant Infections 2021. [DOI: 10.1007/978-3-030-25869-6_67] [Reference Citation Analysis]
11 Dirkx T. Kidney Disease in Hematopoietic Cell Transplantation. Blood and Marrow Transplant Handbook 2021. [DOI: 10.1007/978-3-030-53626-8_35] [Reference Citation Analysis]
12 Basu S, Basu D, Ghara N. Blood Product Support in HSCT. Contemporary Bone Marrow Transplantation 2021. [DOI: 10.1007/978-3-030-36358-1_8] [Reference Citation Analysis]
13 Malyszko J, Basak G, Batko K, Capasso G, Capasso A, Drozd-Sokolowska J, Krzanowska K, Kulicki P, Matuszkiewicz-Rowinska J, Soler MJ, Sprangers B, Malyszko J. Haematological disorders following kidney transplantation. Nephrol Dial Transplant 2020:gfaa219. [PMID: 33150431 DOI: 10.1093/ndt/gfaa219] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 1.0] [Reference Citation Analysis]
14 Fornwalt RA, Brigham EP, Scott Stephens R. Critical Care of Hematopoietic Stem Cell Transplant Patients. Crit Care Clin 2021;37:29-46. [PMID: 33190774 DOI: 10.1016/j.ccc.2020.08.002] [Cited by in Crossref: 5] [Cited by in F6Publishing: 6] [Article Influence: 2.5] [Reference Citation Analysis]
15 Bray MA, Sartain SE, Gollamudi J, Rumbaut RE. Microvascular thrombosis: experimental and clinical implications. Transl Res 2020;225:105-30. [PMID: 32454092 DOI: 10.1016/j.trsl.2020.05.006] [Cited by in Crossref: 37] [Cited by in F6Publishing: 29] [Article Influence: 18.5] [Reference Citation Analysis]
16 Hildebrandt GC, Chao N. Endothelial cell function and endothelial-related disorders following haematopoietic cell transplantation. Br J Haematol 2020;190:508-19. [PMID: 32319084 DOI: 10.1111/bjh.16621] [Cited by in Crossref: 21] [Cited by in F6Publishing: 23] [Article Influence: 10.5] [Reference Citation Analysis]
17 Stephens RS. ICU Complications of Hematopoietic Stem Cell Transplant, Including Graft vs Host Disease. Evidence-Based Critical Care 2020. [DOI: 10.1007/978-3-030-26710-0_80] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.5] [Reference Citation Analysis]
18 Miller R, Schlueter A. Transplant Infectious Disease Evaluation of Cytopenias. Emerging Transplant Infections 2020. [DOI: 10.1007/978-3-030-01751-4_67-1] [Reference Citation Analysis]
19 Mueller NJ. Changing Definition of Immunosuppression: Targeted Therapies and Resulting Emerging Infections and Their Prevention. Emerging Transplant Infections 2020. [DOI: 10.1007/978-3-030-01751-4_13-1] [Reference Citation Analysis]
20 Basu S, Basu D, Ghara N. Blood Product Support in HSCT. Contemporary Bone Marrow Transplantation 2020. [DOI: 10.1007/978-3-319-64938-2_8-1] [Reference Citation Analysis]
21 Wall SA, Zhao Q, Yearsley M, Blower L, Agyeman A, Ranganathan P, Yang S, Wu H, Bostic M, Jaglowski S, Brammer JE, William B, Choe H, Mims AS, Penza S, Efebera Y, Devine S, Cataland S, Davies SM, Vasu S. Complement-mediated thrombotic microangiopathy as a link between endothelial damage and steroid-refractory GVHD. Blood Adv. 2018;2:2619-2628. [PMID: 30327370 DOI: 10.1182/bloodadvances.2018020321] [Cited by in Crossref: 34] [Cited by in F6Publishing: 36] [Article Influence: 11.3] [Reference Citation Analysis]
22 造血幹細胞移植後血栓性微小血管症の診断と治療. Nihon Kessen Shiketsu Gakkaishi 2019;30:160-163. [DOI: 10.2491/jjsth.30.160] [Reference Citation Analysis]
23 Chaturvedi S, George B, Savani BN. Bleeding and Thrombotic Complications. In: Carreras E, Dufour C, Mohty M, Kröger N, editors. The EBMT Handbook. Cham: Springer International Publishing; 2019. pp. 301-6. [DOI: 10.1007/978-3-030-02278-5_40] [Reference Citation Analysis]
24 Wanchoo R, Bayer RL, Bassil C, Jhaveri KD. Emerging Concepts in Hematopoietic Stem Cell Transplantation-Associated Renal Thrombotic Microangiopathy and Prospects for New Treatments. Am J Kidney Dis 2018;72:857-65. [PMID: 30146419 DOI: 10.1053/j.ajkd.2018.06.013] [Cited by in Crossref: 26] [Cited by in F6Publishing: 28] [Article Influence: 6.5] [Reference Citation Analysis]
25 Rudoni J, Jan A, Hosing C, Aung F, Yeh J. Eculizumab for transplant-associated thrombotic microangiopathy in adult allogeneic stem cell transplant recipients. Eur J Haematol 2018;101:389-98. [PMID: 29920784 DOI: 10.1111/ejh.13127] [Cited by in Crossref: 27] [Cited by in F6Publishing: 32] [Article Influence: 6.8] [Reference Citation Analysis]
26 Winthrop KL, Mariette X, Silva JT, Benamu E, Calabrese LH, Dumusc A, Smolen JS, Aguado JM, Fernández-Ruiz M. ESCMID Study Group for Infections in Compromised Hosts (ESGICH) Consensus Document on the safety of targeted and biological therapies: an infectious diseases perspective (Soluble immune effector molecules [II]: agents targeting interleukins, immunoglobulins and complement factors). Clin Microbiol Infect 2018;24 Suppl 2:S21-40. [PMID: 29447987 DOI: 10.1016/j.cmi.2018.02.002] [Cited by in Crossref: 121] [Cited by in F6Publishing: 95] [Article Influence: 30.3] [Reference Citation Analysis]
27 Weitz IC. Thrombotic microangiopathy in cancer. Thromb Res 2018;164 Suppl 1:S103-5. [PMID: 29703465 DOI: 10.1016/j.thromres.2018.01.014] [Cited by in Crossref: 13] [Cited by in F6Publishing: 14] [Article Influence: 3.3] [Reference Citation Analysis]
28 Benamu E, Montoya JG. Infections associated with the use of eculizumab: recommendations for prevention and prophylaxis. Curr Opin Infect Dis 2016;29:319-29. [PMID: 27257797 DOI: 10.1097/QCO.0000000000000279] [Cited by in Crossref: 87] [Cited by in F6Publishing: 90] [Article Influence: 21.8] [Reference Citation Analysis]
29 Zhang XH, Liu X, Wang QM, He Y, Zhu XL, Zhang JM, Han W, Chen H, Chen YH, Wang FR, Wang JZ, Zhang YY, Mo XD, Chen Y, Wang Y, Fu HX, Chang YJ, Xu LP, Liu KY, Huang XJ. Thrombotic microangiopathy with concomitant GI aGVHD after allogeneic hematopoietic stem cell transplantation: Risk factors and outcome. Eur J Haematol 2018;100:171-81. [PMID: 29114931 DOI: 10.1111/ejh.12996] [Cited by in Crossref: 8] [Cited by in F6Publishing: 9] [Article Influence: 1.6] [Reference Citation Analysis]
30 Chaudhary RK, Dhakal P, Aryal A, Bhatt VR. Central nervous system complications after allogeneic hematopoietic stem cell transplantation. Future Oncol 2017;13:2297-312. [PMID: 28984145 DOI: 10.2217/fon-2017-0274] [Cited by in Crossref: 13] [Cited by in F6Publishing: 13] [Article Influence: 2.6] [Reference Citation Analysis]
31 Khosla J, Yeh AC, Spitzer TR, Dey BR. Hematopoietic stem cell transplant-associated thrombotic microangiopathy: current paradigm and novel therapies. Bone Marrow Transplant 2018;53:129-37. [DOI: 10.1038/bmt.2017.207] [Cited by in Crossref: 67] [Cited by in F6Publishing: 69] [Article Influence: 13.4] [Reference Citation Analysis]
32 Zeisbrich M, Becker N, Benner A, Radujkovic A, Schmitt K, Beimler J, Ho AD, Zeier M, Dreger P, Luft T. Transplant-associated thrombotic microangiopathy is an endothelial complication associated with refractoriness of acute GvHD. Bone Marrow Transplant 2017;52:1399-405. [PMID: 28650448 DOI: 10.1038/bmt.2017.119] [Cited by in Crossref: 45] [Cited by in F6Publishing: 47] [Article Influence: 9.0] [Reference Citation Analysis]
33 Brocklebank V, Kavanagh D. Complement C5-inhibiting therapy for the thrombotic microangiopathies: accumulating evidence, but not a panacea. Clin Kidney J 2017;10:600-24. [PMID: 28980670 DOI: 10.1093/ckj/sfx081] [Cited by in Crossref: 33] [Cited by in F6Publishing: 34] [Article Influence: 6.6] [Reference Citation Analysis]
34 Yeates L, Slatter MA, Bonanomi S, Lim FLWI, Ong SY, Dalissier A, Barberi W, Shulz A, Duval M, Heilmann C, Willekens A, Hwang WHY, Uderzo C, Bader P, Gennery AR. Use of defibrotide to treat transplant-associated thrombotic microangiopathy: a retrospective study of the Paediatric Diseases and Inborn Errors Working Parties of the European Society of Blood and Marrow Transplantation. Bone Marrow Transplant 2017;52:762-4. [PMID: 28092354 DOI: 10.1038/bmt.2016.351] [Cited by in Crossref: 27] [Cited by in F6Publishing: 30] [Article Influence: 5.4] [Reference Citation Analysis]
35 Cardinale M, Owusu K, Malm T. Blood, Blood Components, Plasma, and Plasma Products. Side Effects of Drugs Annual 2017. [DOI: 10.1016/bs.seda.2017.06.011] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.2] [Reference Citation Analysis]
36 Moreau AS, Bourhis JH, Contentin N, Couturier MA, Delage J, Dumesnil C, Gandemer V, Hichri Y, Jost E, Platon L, Jourdain M, Pène F, Yakoub-Agha I. [Transfer of allogeneic stem cell transplant recipients to the intensive care unit: Guidelines from the Francophone society of marrow transplantation and cellular therapy (SFGM-TC)]. Bull Cancer 2016;103:S220-8. [PMID: 27816169 DOI: 10.1016/j.bulcan.2016.09.008] [Cited by in Crossref: 6] [Cited by in F6Publishing: 6] [Article Influence: 1.0] [Reference Citation Analysis]
37 Sahin U, Ataca Atilla P, Atilla E, Toprak SK, Demirer T. An overview of hematopoietic stem cell transplantation related thrombotic complications. Critical Reviews in Oncology/Hematology 2016;107:149-55. [DOI: 10.1016/j.critrevonc.2016.09.004] [Cited by in Crossref: 15] [Cited by in F6Publishing: 17] [Article Influence: 2.5] [Reference Citation Analysis]
38 Dhakal P, Bhatt VR. Is complement blockade an acceptable therapeutic strategy for hematopoietic cell transplant-associated thrombotic microangiopathy? Bone Marrow Transplant 2017;52:352-6. [PMID: 27775697 DOI: 10.1038/bmt.2016.253] [Cited by in Crossref: 22] [Cited by in F6Publishing: 23] [Article Influence: 3.7] [Reference Citation Analysis]
39 Jodele S, Dandoy CE, Myers KC, El-Bietar J, Nelson A, Wallace G, Laskin BL. New approaches in the diagnosis, pathophysiology, and treatment of pediatric hematopoietic stem cell transplantation-associated thrombotic microangiopathy. Transfus Apher Sci. 2016;54:181-190. [PMID: 27156964 DOI: 10.1016/j.transci.2016.04.007] [Cited by in Crossref: 69] [Cited by in F6Publishing: 78] [Article Influence: 11.5] [Reference Citation Analysis]
40 Pulsipher MA. Fishing for complements. Blood 2016;127:957-8. [PMID: 26917734 DOI: 10.1182/blood-2015-12-685131] [Reference Citation Analysis]